Bio-Techne (NASDAQ: TECH) reported Q3 EPS of $0.53, in-line with the analyst estimate of $0.53. Revenue for the quarter came in at $294.1 million versus the consensus estimate of $296.61 million.

For earnings history and earnings-related data on Bio-Techne (TECH) click here.